STOCK TITAN

Allogene (NASDAQ: ALLO) exec share sale is tax ‘sell to cover’

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. (ALLO) reported that officer Douglas Earl Martin, SVP and General Counsel, sold 29,697 shares of common stock on August 21, 2026 at $2.12 per share. The shares were sold to cover tax withholding on vesting RSUs under a mandated "sell to cover" arrangement, so the trade was not discretionary. After this and related adjustments, including forfeiture of performance RSUs and prior ESPP purchases, he directly holds 488,267 shares of Allogene common stock.

Positive

  • None.

Negative

  • None.
Insider Douglas Earl Martin
Role SVP, General Counsel
Sold 29,697 shs ($63K)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 29,697 $2.12 $63K
Holdings After Transaction: Common Stock — 488,267 shares (Direct)
Footnotes (3)
  1. F1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  2. F2. Reflects forfeiture of 54,479 shares subject to performance RSUs granted to the Reporting Person on August 14, 2023.
  3. F3. Includes 7,495 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
Shares sold 29,697 shares Common stock sold on August 21, 2026 to cover tax withholding
Sale price per share $2.12 per share Price for the 29,697-share sale on August 21, 2026
Shares owned after transaction 488,267 shares Direct holdings of Douglas Earl Martin after reported changes
Forfeited performance RSUs 54,479 shares Shares subject to performance RSUs granted August 14, 2023 that were forfeited
ESPP shares included 7,495 shares Shares acquired March 15, 2026 under employee stock purchase program
restricted stock units financial
"in connection with the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sell to cover financial
"funded by a "sell to cover" transaction and does not represent"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
performance RSUs financial
"forfeiture of 54,479 shares subject to performance RSUs granted"
Performance RSUs are promises to deliver company shares to executives or employees only if the business meets preset goals such as revenue, profit, stock price, or operational targets. They matter to investors because they align management pay with measurable company results and can affect the number of shares outstanding and future earnings per share once the shares are issued. Think of them as a bonus paid in stock that only arrives if the team hits the agreed milestones.
employee stock purchase program financial
"acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program"

FAQ

What insider transaction did ALLO report for Douglas Earl Martin on August 21, 2026?

Allogene reported that Douglas Earl Martin sold 29,697 shares of common stock on August 21, 2026 at $2.12 per share. The sale covered tax withholding obligations related to vesting restricted stock units and was executed under a mandated "sell to cover" arrangement.

Was the August 21, 2026 sale by ALLO executive Douglas Earl Martin a discretionary trade?

No. The filing states the 29,697-share sale was mandated by Allogene’s equity incentive plan as a "sell to cover" transaction for tax withholding on vesting RSUs and "does not represent a discretionary trade" by Douglas Earl Martin.

How many ALLO shares does Douglas Earl Martin hold after the reported Form 4 transaction?

Following the reported sale and related adjustments, Douglas Earl Martin directly holds 488,267 shares of Allogene Therapeutics common stock, according to the Form 4 data.

What price per share was received in the ALLO insider sale on August 21, 2026?

The Form 4 reports that the 29,697 shares of Allogene common stock were sold at a price of $2.12 per share in an open market or private transaction.

What additional equity changes for Douglas Earl Martin are noted in the ALLO Form 4 footnotes?

Footnotes state that 54,479 shares subject to performance RSUs granted on August 14, 2023 were forfeited, and holdings now include 7,495 shares acquired on March 15, 2026 through an employee stock purchase program.

Was the ALLO insider transaction reported as under a Rule 10b5-1 trading plan?

No. The Rule 10b5-1 checkbox is not marked as an affirmative plan transaction, and the footnote explains the sale was due to the issuer’s tax withholding "sell to cover" election, not a discretionary or separate 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Douglas Earl Martin

(Last)(First)(Middle)
210 EAST GRAND AVE

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/21/2026S29,697(1)D$2.12488,267(2)(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
2. Reflects forfeiture of 54,479 shares subject to performance RSUs granted to the Reporting Person on August 14, 2023.
3. Includes 7,495 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
Remarks:
/s/Earl Douglas08/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)